MD Anderson Cancer Center and Artios Pharma reach agreement to develop anti-cancer ATR inhibitors

The agreement gives Artios exclusive rights to the attad agency for exclusive research, development, manufacture and commercialization of the ATR inhibitor worldwideArtios plans to submit an application for a new drug study of the candidate compound in the second half of 2020
The ATR Inhibitor Program is the result of extensive collaboration between the drug discovery team at the MD Anderson Center and ShangPharmaATR inhibitors are primarily targeted at inhibiting ATR kinase, which prevents DNA damage checkpoint activation, destroys DNA damage repair and induces tumor apoptosisATR is an important signaling protein in DNA double-stranded fracture repair and replication stressBy inhibiting ATR, tumors with ATM defects can be selectively killed through a concept called synthetic lethalityHigh levels of ATM mutations and protein loss have been identified in many different tumor types, creating important opportunities for clinical ATR inhibitorsBased on MD Anderson's clinical observations, Discovery, in collaboration with ShangPharma and its affiliate, ChemPartner, has developed small molecule inhibitors for DDR that benefit a wide range of cancer patients(Bio Valley/Bioon.com)original source: MD Anderson, Artios Pharma and Shang Pharma announce in-licensing agreement for DNA damage sip pontoon